GlassScriptPhysician profile
Derrick O Hull
NPI 1659687499
$4,741.96
in general payments reported to CMS, 2019-2025
25 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $1,361 · 2023: $964 · 2024: $751 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,822.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,235.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $587.52 | 2022-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $465.27 | 2022-2025 | Arexvy, Bexsero |
| Abbvie INC. | $459.58 | 2021-2025 | |
| Lilly USA, LLC | $377.37 | 2024-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $270.69 | 2024-2025 | Comet, Avvigo Guidance System, Opticross |
| E.R. Squibb & Sons, L.L.C. | $249.82 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $158.57 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $156.18 | 2025 | Breztri, Airsupra |
| Neurelis, INC. | $125.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2022 | |
| Pfizer INC. | $119.39 | 2023 | |
| Sanofi Pasteur INC. | $103.61 | 2023-2025 | |
| Amgen INC. | $43.59 | 2022-2023 | Repatha, Otezla |
| Exact Sciences Corporation | $40.87 | 2024-2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.33 | 2022 | |
| Corcept Therapeutics | $31.70 | 2024-2025 | Korlym |
| Phadia US INC. | $24.14 | 2024 | Immunocap |
| Abbott Laboratories | $24.08 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.49 | 2024 | Gvoke Hypopen |
| Antares Pharma, INC. | $19.87 | 2023 | Nocdurna, Tlando, Xyosted |
| Dexcom, INC. | $18.39 | 2025 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $15.19 | 2024 | Doc Band |
| Sobi, INC | $14.27 | 2021 | |
| Sumitomo Pharma America, INC. | $14.14 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.